Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ENLV
STRONG SELLEnlivex Ltd. · Healthcare · Israel · $71M · Avg Vol: $556K/d
COMPANY DESCRIPTION
Enlivex Ltd. is a clinical-stage biotechnology company focused on developing Allocetra™, a novel cell-based immunotherapy designed to rebalance the immune system in patients suffering from life-threatening inflammatory and autoimmune conditions. The company's competitive edge lies in its unique approach to modulating the immune system, aiming to prevent and reverse cytokine storms and organ dysfunction. It operates as a specialized biotech firm, with its lead candidate showing promise in severe indications such as sepsis and COVID-19.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -12.15 | -1.85 | -1.72 | -1.03 | — | — | — | -1.15 | -0.21 | — |
| Shares | — | 16.8M | 16.8M | 16.8M | 15.8M | -6.0% | 16.8M | — | — | — |
| Debt | — | 4.8M | 1.0M | 0.5M | 0.6M | -49.1% | 0.6M | — | — | — |
| Equity | — | 56.8M | 30.1M | 23.6M | 1.9B | 224.1% | — | — | — | — |
| Op CF | — | -24.0M | -23.5M | -13.0M | -10.4M | — | -10.4M | — | — | — |
| Inv CF | — | 62.5M | -26.0M | 9.1M | -1.3M | — | — | — | — | — |
| Fin CF | — | 0.1M | 0.4M | 6.5M | 10.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ENLV are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ENLV | Enlivex Ltd.(you) | $71M | 12 | STRONG SELL |
| PYPD | PolyPid Ltd. | $75M | 21 | SELL |
| ENTX | Entera Bio Ltd. | $101M | 17 | STRONG SELL |
| MDWD | MediWound Ltd. | $183M | 8 | STRONG SELL |
| SLGL | Sol-Gel Technologies Ltd. | $268M | 33 | SELL |
| DRTS | Alpha Tau Medical Ltd. | $1.1B | 26 | SELL |
| NNOX | Nano-X Imaging Ltd. | $62M | 8 | STRONG SELL |
| CGEN | Compugen Ltd. | $216M | 98 | STRONG BUY |
| INCR | InterCure Ltd. | $55M | 36 | HOLD |
| BVC.L | BATM Advanced Communications Ltd. | $67M | 51 | HOLD |
Peer medians: ROE -2.9% · P/E 20.4x · Gross margin 36.8%